AGS 16C3F

Drug Profile

AGS 16C3F

Alternative Names: AGS-16C3F; AGS-16M8F; Anti-ENPP3-MMAF

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Agensys
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Renal cell carcinoma

Most Recent Events

  • 26 Apr 2017 Agensys and Astellas Pharma completes a phase I trial for Renal cell carcinoma (Metastatic disease, Second-line therapy or greater) in USA (NCT01672775)
  • 31 Jan 2017 Phase-II clinical trials in Renal cell carcinoma in Europe (IV) (Astellas Pharma pipeline, January 2017)
  • 01 Feb 2016 Phase-II clinical trials in Renal cell carcinoma (Second-line therapy or greater, Metastatic disease) in USA, Canada (IV) (NCT02639182)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top